1) they might owe a milestone payment to Astellas now or later, they inlicensed it, cf. "VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma." http://www.vical.com/products/VL-2397/default.aspx
the current indication seems fine a) immunocompromised people, like such having received a transplant and being on an immunosuppressive drug, with resistant candida glabrata) ... this appears to be a problem and b) the new FDA has opened an avenue for bringing it quicker to the market (<--- this is actually the only message of the press statement)
... so the next question would be some check of epidemiology, prices and (of course) extrapolation/educated guess of a clinical success.